Dassault Aviation SA (0IAX)
London Exchange · UK · prices in EUR · close of 15 Oct 2026
Key indicators
| Last close | EUR 298.00 |
|---|---|
| 52-week range | 256.60 – 355.71 |
| Return, 1 month / 3 months | +5.9% / +5.2% |
| Return, 1 year / 3 years | +12.3% / +66.8% |
| Trend | Below its 200-day average |
| RSI (14) | 62 |
| Volatility (1 year) | 29.3% |
| Worst drawdown (1 year) | -21.1% |
| Average daily value traded | 4.24M EUR |
| Dividend yield | 1.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Dassault Aviation is a French aerospace company that designs and builds military aircraft and business jets. Its defence work centres on the Rafale fighter, flown by the French armed forces and sold to several other countries, along with unmanned aircraft and related systems. For corporate and private customers it produces the Falcon family of business jets. The company is based in France, with manufacturing and support operations there and in other countries, and it also holds a stake in Thales.
On this site Dassault Aviation SA appears as a stock on the London Exchange (UK), code 0IAX, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Dassault Aviation SA (0IAX) trades on the London Exchange in UK. It last closed at EUR 298.00 on 15 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 1,719 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 12.3% and over the last three months it rose 5.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 43 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -2.1% | ||
| From 52-week high | -14.2% | ||
| Momentum | 52 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 5.2% | ||
| 6-month return | -5.6% | ||
| 12-month return, skipping the last month | 6.1% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.1% | ||
| Liquidity | 66 · Fair | Moderate trading activity. | |
| Average daily value traded | 4.24M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 48 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.6% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Income: Dividend is small or irregular.
Returns
| 1 week | +6.8% |
|---|---|
| 1 month | +5.9% |
| 3 months | +5.2% |
| 6 months | −5.6% |
| 1 year | +12.3% |
| 3 years | +66.8% |
| 5 years | +245.9% |
Signals
| 50-day / 200-day average | 291.50 / 304.40 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.24 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 May 2026 | EUR 4.7800 |
| 20 May 2025 | EUR 4.7200 |
| 20 May 2024 | EUR 3.3700 |
| 19 May 2023 | EUR 3.0000 |
| 23 May 2022 | EUR 2.4900 |
| 18 May 2021 | EUR 123.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.